Stephanie Deshayes
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2019First federal award
$12.0MFederal grants as PI11 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
11 awards · $12.0M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 17, 2026 | NIH | SBIR Phase II MOSAIC II: A Randomized Clinical Study of the MAP Wound Matrix to Reduce Time to Graft-Readiness after Non-Melanoma Skin Cancer Resection | $1.4M | Tempo Therapeutics Inc |
| Jun 15, 2023 | NSF | STTR Phase II STTR Phase II:VaxMAP a single dose multivalent vaccine to produce durable and cross-reactive immunity against various coronaviruses | $1.0M | Tempo Therapeutics Inc with YALE UNIVERSITY |
| Jun 12, 2023 | NSF | STTR Phase II STTR Phase II: VaxMAP a single dose multivalent vaccine to produce durable and cross-reactive immunity against various coronaviruses | $1.0M | Tempo Therapeutics Inc |
| Sep 1, 2022 | NIH | SBIR Phase II A first in human clinical study of TT101, a synthetic immunomodulatory material to build new functional tissue over exposed bone as a one time treatment for diabetic limb preservation patients | $1.2M | Tempo Therapeutics Inc |
| Sep 15, 2021 | NIH | SBIR Phase II A first in human clinical study of TT101, a synthetic immunomodulatory material to build new functional tissue over exposed bone as a one time treatment for diabetic limb preservation patients | $1.4M | Tempo Therapeutics Inc |
| Sep 15, 2021 | NIH | SBIR Phase II A first in human clinical study of TT101, a synthetic immunomodulatory material to build new functional tissue over exposed bone as a one time treatment for diabetic limb preservation patients | $2.5M | Tempo Therapeutics Inc |
| Sep 2, 2020 | NSF | SBIR Phase I SBIR Phase I: A new vaccine technology to engineer a potent and polarized immunity against COVID-19 | $256K | Tempo Therapeutics Inc |
| Aug 17, 2020 | NIH | SBIR Phase II MAP: a Flowable, Precision-Engineered, and Tunable Tissue Scaffold Leveraging Hyper-Porous Geometry to Control Inflammation and Promote Regenerative Healing in Diabetic Wounds | $837K | Tempo Therapeutics Inc |
| May 6, 2020 | NIH | SBIR Phase II Diversity supplement for Oliver Viyar to receive research training in tissue engineering. | $25K | Tempo Therapeutics Inc |
| Sep 15, 2019 | NIH | SBIR Phase II MAP: a Flowable, Precision-Engineered, and Tunable Tissue Scaffold Leveraging Hyper-Porous Geometry to Control Inflammation and Promote Regenerative Healing in Diabetic Wounds | $1.6M | Tempo Therapeutics Inc |
| Sep 10, 2019 | NIH | SBIR Phase II MAP: a Flowable, Precision-Engineered, and Tunable Tissue Scaffold Leveraging Hyper-Porous Geometry to Control Inflammation and Promote Regenerative Healing in Diabetic Wounds | $737K | Tempo Therapeutics Inc |
1 patents as inventor
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#42
Awards as PI#106
Patents#273
Companies
- Tempo Therapeutics IncLinked by awards · Biotech
Research institutions
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.